Important Safety Information
If you have following problem , consult with your healthcare provider before taking regorafenib
Liver Problem
Bleeding problem
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Special features of Regonix-
- Convenient once oral daily dosing schedule
- Increase disease control rate
- Enhance survival rate
INDICATIONS
Colorectal Cancer
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with Fluoropyrimidine-, Oxaliplatin- and Irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wildtype, an anti-EGFR therapy.
Gastrointestinal Stromal Tumors
Regorafenib is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with Imatinib mesylate and Sunitinib malate.
Hepatocellular Carcinoma
Regorafenib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Sorafenib.
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.
Registered and Licensed by Regulatory Authority of Bangladesh
Regonix is a registered product by the Directorate General of Drug Administration & Licensing Authority (Drugs) of Bangladesh. Drug Registration Number: 341-310-010 Inclusion Date: 30-01-2017 Valid up to: 29-04-2022